Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded manufacturing capacity remain strong. Read more on NVO stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback